GSK Pulls Autism Drug Application After Regulator Pushback
GlaxoSmithKline (GSK) has withdrawn its application for broader use of a drug linked to autism treatment. This decision follows regulators’ determination that the evidence does not support expanded approval for autism. The move highlights ongoing challenges in approving treatments for neurodevelopmental disorders. Key Points GSK withdraws drug application for autism use Regulators cite insufficient evidence […]
GSK Pulls Autism Drug Application After Regulator Pushback Read More »